 |
|
|
| |
Comparison of lipid profile with nevirapine versus atazanavir/ritonavir, both combined with tenofovir DF and emtricitabine (TDF/FTC), in treatment-naïve HIV-1 infected patients: ARTEN Study Week 48 results
|
| |
| |
Reported by Jules Levin
EACS Nov 13 2009, Cologne, Germany
D Podzamczer1, V Soriano2, J Andrade-Villanueva3, B Clotet4, S Taylor5,
J Rockstroh6, P Domingo7, P Reiss8, HJ Gellermann9, V Cairns9, L de Rossi9
1. Hospital Universitario de Bellvitge, Barcelona, Spain; 2. Hospital Carlos III, Madrid, Spain; 3. Antiguo Hospital Civil de Guadalajara, Guadalajara, Mexico; 4. Hospital Universitari Germans Trias i Pujol and irsiCaixa Foundation, Barcelona, Spain; 5. Birmingham Heartlands Hospital, Birmingham, UK; 6. University of Bonn, Bonn, Germany; 7. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 8. Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; and 9. Boehringer Ingelheim, Ingelheim, Germany
Soriano et al. IAS 2009, Cape Town, South Africa, Poster LBPE07.
Nevirapine is not indicated for qd dosing. The safety
and efficacy of qd dosing have not been established
|
| |
|
|
|
|
|
